Home » Rubraca Approved for Ovarian Cancer Maintenance Treatment
Rubraca Approved for Ovarian Cancer Maintenance Treatment
The FDA approved Clovis Oncology’s Rubraca (rucaparib) as a maintenance treatment for recurrent ovarian cancer.
The treatment is applicable for adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.
Rubraca previously received regular approval as an earlier-line therapy based on positive data from the phase 3 clinical trial.
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May